A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2007
At a glance
- Drugs Adalimumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 05 Nov 2007 Status changed from initiated to withdrawn prior to recruitment.
- 20 Aug 2007 New trial record.